Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Advaxis' Listeria Monocytogenes-Based Vaccine Garners National Media Attention
May 7th, 2008
Advaxis Inc., (OTCBB: ADXS, http://www.advaxis.com.), a developmental biotechnology company, garnered national media attention after having presented landmark results from it's first-in-man clinical trial of its flagship drug candidate, Lovaxin C - a live Listeria monocytogenes-based cancer vaccine - at the annual meeting of the American Association for Cancer Research ("AACR"), held earlier this week in San Diego, CA. Amanda Gardner, a health journalist with U.S. News & World Report, reported that Listeria, a common bacterium found in leafy vegetables and dairy products, might be the next weapon in the fight against cervical cancer, a major cause of death among women...
Source: Vaccine Weekly (2008-05-07)
|
